Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 476

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

Open access
Law, R E, Meehan, W P, Xi, X P, Graf, K, Wuthrich, D A, Coats, W, Faxon, D, Hsueh, W A·1996·Journal of Clinical Investigation

Abstract

Vascular smooth muscle cell (VSMC) proliferation and migration are responses to arterial injury that are highly important to the processes of restenosis and atherosclerosis.In the arterial balloon injury model in the rat, platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) are induced in the vessel wall and regulate these VSMC activities.Novel insulin sensitizing agents, thiazolidinediones, have been demonstrated to inhibit insulin and epidermal growth factor-induced growth of VSMCs.We hypothesized that these agents might also inhibit the effect of PDGF and bFGF on cultured VSMCs and intimal hyperplasia in vivo.Troglitazone (1 M), a member of the thiazolidinedione class, produced a near complete inhibition of both bFGF-induced DNA synthesis as measured by bromodeoxyuridine incorporation (6.5 Ϯ 3.9 vs. 17.6 Ϯ 4.3% cells labeled, P Ͻ 0.05) and c-fos induction.This effect was associated with an inhibition (by 73 Ϯ 4%, P Ͻ 0.01) by troglitazone of the transactivation of the serum response element, which regulates c-fos expression.Inhibition of c-fos induction by troglitazone appeared to occur via a blockade of the MAP kinase pathway at a point downstream of MAP kinase activation by MAP kinase kinase.At this dose, troglitazone also inhibited PDGF-BB-directed migration of VSMC (by 70 Ϯ 6%, P Ͻ 0.01).These in vitro effects were operative in vivo.Quantitative image analysis revealed that troglitazone-treated rats had 62% ( P Ͻ 0.001) less neointima/media area ratio 14 d after balloon injury of the aorta compared with injured rats that received no troglitazone.These results suggest troglitazone is a potent inhibitor of VSMC proliferation and migration and, thus, may be a useful agent to prevent restenosis and possibly atherosclerosis.( J. Clin.Invest.1996.98:1897-1905.)Key words: restenosis • plateletderived growth factor • basic fibroblast growth factor • c-fos • MAP kinase Methods Materials.Materials were obtained from the following suppliers.PDGF-BB, DMEM, FBS, bromodeoxyuridine (BrdU), alkaline phosphatase-conjugated anti-mouse IgG antibody, monoclonal antibody against smooth muscle ␣ -actin, and myelin basic protein (MBP) were from Sigma Chemical Co.(St.Louis, MO).Culture plastic ware was from Falcon Labware (Lincoln Park, NJ).bFGF was from R&D Systems (Minneapolis, MN).Mouse anti-BrdU monoclonal antibody was from Zymed Laboratories, Inc. (South San Francisco, CA).Troglitazone and PD 98059 were a generous gift from Parke-Davis (Ann

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci118991

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 476

Metadata

Authors
Law, R. E., Meehan, W. P., Xi, X. P., Graf, K., Wuthrich, D. A., Coats, W., Faxon, D., & Hsueh, W. A.
Venue
Journal of Clinical Investigation
Published
1996-10-15
Volume
98
Issue
8
Pages
1897-1905
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2090412760
Cited by
476
References
59
FWCI
7.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. https://app.cochat.ai/papers/10.1172/jci118991
The paper
Law, R. E., Meehan, W. P., Xi, X. P., Graf, K., Wuthrich, D. A., Coats, W., Faxon, D., & Hsueh, W. A. (1996). Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. Journal of Clinical Investigation. https://doi.org/10.1172/jci118991

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.